With PRVB and Sanofi it was interesting. Expected

With PRVB and Sanofi it was interesting. Expected but a little out of the blue at the same time. Pre-buyout, Sanofi was required to buy $35 million in PRVB stock at a 40% premium to the share price as part of their (pre-buyout) agreement. Oddly, it was PRVB that was to determine the 5 day stretch that would create the price Sanofi paid and they didn't choose a high stretch. Instead, they waited until the price had dropped and it was close to the end of the timeframe in which they had to execute the purchase, and I think Sanofi paid something like $12 and change per share instead of what could have been $15. From that point forward, and it wasn't long, the price had selling pressure more days than not until the buyout occurred and fell to around $6.90 before the announcement of $25/share. Could have been market dynamics bringing the price down but the conspiracy theorist in me says that the price was somehow purposely suppressed by Sanofi. I mean, buyout speculation was rampant and the drug was on the market with news agencies putting out stories of patients getting the treatment. Earnings were a week or so away, too. People were anxious to see what the company had to say about total patients treated, insurance coverage updates, etc. It feels like they were trying to finalize buying Provention and if the share price were to move in a positive direction their $25/share price wouldn't have been attractive. But who knows. I've seen 300% jumps in price for biotechs announcing phase 1 trial success. Congrats! It didn't kill anyone with side effects and the bloodwork shows there was an effect. Let's triple the market cap!